Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Edgewise Therapeutics ( (EWTX) ) has provided an announcement.
Edgewise Therapeutics announced positive topline results from their Phase 2 CANYON trial of sevasemten for treating individuals with Becker muscular dystrophy. The study, which is the largest of its kind, successfully met its primary endpoint by showing a significant reduction in creatine kinase levels, a biomarker of muscle damage. The key secondary endpoint of functional stabilization using the North Star Ambulatory Assessment also showed promising trends. Sevasemten was well-tolerated with no new safety concerns. The results support further development and suggest potential for the GRAND CANYON pivotal cohort to demonstrate significant outcomes, which could pave the way for future regulatory filings and the first approved treatment for Becker muscular dystrophy.
More about Edgewise Therapeutics
Edgewise Therapeutics is a leading biopharmaceutical company in the muscle disease industry, focused on developing treatments for muscular dystrophies. The company’s primary product is sevasemten, an orally administered fast skeletal myosin inhibitor aimed at protecting muscle against contraction-induced damage. Their market focus is on rare neuromuscular disorders like Becker muscular dystrophy.
YTD Price Performance: 152.47%
Average Trading Volume: 1,117,054
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.62B
See more insights into EWTX stock on TipRanks’ Stock Analysis page.
